The report analyzes and forecasts the oncology biosimilars market at global and regional levels. The market has been forecast based on volume (Tons) and value (US$ Mn) from 2019 to 2026. The study includes drivers and restraints of the global market. It covers the impact of these drivers and restraints on the demand during the forecast period. The report also highlights opportunities in the market at the global level. For the region and all segments, the sales, revenue and their market share, growth rate are key research objects; we can research the manufacturers' sales, price, revenue, cost and gross profit and their changes. What's more, we will display the main consumers, raw material manufacturers, distributors, etc.
This report first introduces the background of oncology biosimilars, including the definition, classification, application, industrial chain structure, industry overview, national policy and planning analysis of the industry, and the latest dynamic analysis. With regard to production bases and technologies, the research in this report covers the production time, base distribution, technical parameters, research and development trends, technology sources, and sources of raw materials of major oncology biosimilars companies.
Regarding the analysis of the industry chain, the research of this report covers the raw materials and equipment of oncology biosimilars upstream, downstream customers, marketing channels, industry development trends and investment strategy recommendations. The more specific analysis also includes the main application areas of oncology biosimilars and consumption, major regions and consumption, major global producers, distributors, raw material suppliers, equipment providers and their contact information, industry chain relationship analysis.
The report comprises a detailed value chain analysis, which provides a comprehensive view of the global oncology biosimilars market. The Porter’s Five Forces model has also been included to help understand the competitive landscape of the market. The study encompasses market attractiveness analysis, wherein various applications have been benchmarked based on their market size, growth rate, and general attractiveness.
The study provides a decisive view of the oncology biosimilars market by segmenting it in terms of form and application. The segment has been analyzed based on the present and future trends. Regional segmentation includes the current and projected demand in North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
The report provides size (in terms of volume and value) of oncology biosimilars market for the base year 2018 and the forecast between 2019 and 2026. Market numbers have been estimated based on form and application. Market size and forecast for each application segment have been provided for the global and regional market.
Companies Mentioned in the Report
Some of the prominent participants in the global market for oncology biosimilars are Celltrion Inc., Biocon, STADA Arzneimittel AG, Dr. Reddy’s Laboratories Ltd., Pfizer Inc., Intas Pharmaceuticals Ltd., Sandoz International GmbH, BIOCAD, and Teva Pharmaceutical Industries Ltd.
The global oncology biosimilars market is segmented as follows:
By Drug Class:
By Disease Indication:
By Distribution Channel:
By Geography:
Research Methodology:
In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report.
Primary research represents a bulk of research efforts, supplemented by extensive secondary research. Annual reports, press releases, and relevant documents of key players operating in various application areas have been reviewed for competition analysis and market understanding.
Secondary research also includes recent trends, technical writing, Internet sources, and statistical data from government websites, trade associations, and agencies. These have proved to be reliable, effective, and successful approaches for obtaining precise market data, capturing market participants’ insights, and recognizing business opportunities.
The study objectives of this report are:
Section 01 Preface
1.1 Market Definition and Scope
1.2 Research Highlights
Section 02 Assumptions and Research Methodology
2.1 Assumptions & Acronyms Used
2.2 Research Methodology
Section 03 Executive Summary: Global Oncology Biosimilars Market
3.1 Executive Summary
3.2 Market Opportunity Map
3.3 Market Overview
3.4 Key Industry Developments
3.5 Global Oncology Biosimilars Market Size (US$ Mn) Forecast, 2015–2026
3.6 Global Oncology Biosimilars Market Outlook
Section 04 Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunity
4.4 Key Trends
Section 05 Porter’s Five Force Analysis
Section 06 Oncology Biosimilars: Key Molecules
Section 07 Biosimilars Market Snapshot
Section 08 Cancer Statistics
Section 09 Global Oncology Biosimilars Market Analysis and Forecasts, By Drug Class
9.1 Introduction & Definition
9.2 Key Findings
9.3 Global Oncology Biosimilars Market Value Share, by Drug Class, 2017 and 2026
9.4 Market Attractiveness By Drug Class
9.5 Global Oncology Biosimilars Market Forecast, by Drug Class, 2015-2026
9.5.1 G-CSF
9.5.2 Monoclonal Antibody
9.5.3 Hematopoietic Agents
9.6 Global Oncology Biosimilars Market Analysis, by Drug Class, 2015-2026
9.7 Key Trends
Section 10 Global Oncology Biosimilars Market Analysis and Forecasts, By Disease Indication
10.1 Introduction & Definition
10.2 Key Findings
10.3 Global Oncology Biosimilars Market Value Share, by Disease Indication, 2017 and 2026
10.4 Market Attractiveness By Disease Indication
10.5 Global Oncology Biosimilars Market Forecast, by Disease Indication, 2015-2026
10.5.1 Breast Cancer
10.5.2 Non-Small Cell lung Cancer
10.5.3 Blood Cancer
10.5.3.1 Leukemia
10.5.3.1.1 Myeloid Leukemia
10.5.3.1.2 Chronic Lymphocytic Leukemia
10.5.3.1.3 Others
10.5.3.2 Non-Hodgkin Lymphoma
10.5.4 Colorectal Cancer
10.5.5 Neutropenia
10.5.6 Others
10.6 Global Oncology Biosimilars Market Analysis, by Disease Indication, 2015-2026
10.7 Key Trends
Section 11 Global Oncology Biosimilars Market Analysis and Forecasts, By Distribution Channel
11.1 Introduction & Definition
11.2 Key Findings
11.3 Global Oncology Biosimilars Market Value Share, by Distribution Channel, 2017 and 2026
11.4 Market Attractiveness By Distribution Channel
11.5 Global Oncology Biosimilars Market Forecast, by Distribution Channel, 2015-2026
11.5.1 Hospital Pharmacy
11.5.2 Online Pharmacy
11.5.3 Retail Pharmacy
11.6 Global Oncology Biosimilars Market Analysis, by Distribution Channel, 2015-2026
11.7 Key Trends
Section 12 Global Oncology Biosimilars Market Analysis and Forecasts, By Region
12.1 Global Market Scenario
12.2 Global Oncology Biosimilars Market Value Share, by Region, 2017 and 2026
12.3 Global Oncology Biosimilars Market Attractiveness, by Region, 2017–2026
12.4 Global Oncology Biosimilars Market Size (US$ Mn) Forecast, by Region, 2015–2026
12.4.1 North America
12.4.2 Europe
12.4.3 Asia Pacific
12.4.4 Rest of the World
Section 13 North America Oncology Biosimilars Market Analysis and Forecast
13.1 North America Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2015–2026
13.2 North America Oncology Biosimilars Market Value Share, by Country, 2017 and 2026
13.3 North America Oncology Biosimilars Market Attractiveness, by Country, 2017–2026
13.4 North America Oncology Biosimilars Market Size (US$ Mn) Forecast, by Country, 2015–2026
13.4.1 U.S.
13.4.2 Canada
13.5 North America Oncology Biosimilars Market Value Share, by Drug Class, 2017 and 2026
13.6 North America Oncology Biosimilars Market Attractiveness, by Drug Class, 2017–2026
13.7 North America Oncology Biosimilars Market Size (US$ Mn) Forecast, by Drug Class, 2015–2026
13.7.1 G-CSF
13.7.2 Monoclonal Antibody
13.7.3 Hematopoietic Agents
13.8 North America Oncology Biosimilars Market Value Share, by Disease Indication, 2017 and 2026
13.9 North America Oncology Biosimilars Market Attractiveness, by Disease Indication, 2017–2026
13.10 North America Oncology Biosimilars Market Size (US$ Mn) Forecast, by Disease Indication, 2015–2026
13.10.1 Breast Cancer
13.10.2 Non-Small Cell lung Cancer
13.10.3 Blood Cancer
13.10.3.1 Leukemia
13.10.3.1.1 Myeloid Leukemia
13.10.3.1.2 Chronic Lymphocytic Leukemia
13.10.3.1.3 Others
13.10.3.2 Non-Hodgkin Lymphoma
13.10.4 Colorectal Cancer
13.10.5 Neutropenia
13.10.6 Others
13.11 North America Oncology Biosimilars Market Value Share, by Distribution Channel, 2017 and 2026
13.12 North America Oncology Biosimilars Market Attractiveness, by Distribution Channel, 2017–2026
13.13 North America Oncology Biosimilars Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2026
13.13.1 Hospital Pharmacy
13.13.2 Online Pharmacy
13.13.3 Retail Pharmacy
13.14 Key Trends
Section 14 Europe Oncology Biosimilars Market Analysis and Forecast
14.1 Europe Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2015–2026
14.2 Europe Oncology Biosimilars Market Value Share, by Country, 2017 and 2026
14.3 Europe Oncology Biosimilars Market Attractiveness, by Country, 2017–2026
14.4 Europe Oncology Biosimilars Market Size (US$ Mn) Forecast, by Country, 2015–2026
14.4.1 U.K.
14.4.2 Germany
14.4.3 France
14.4.4 Italy
14.4.5 Russia
14.4.6 Spain
14.4.7 Rest of Europe
14.5 Europe Oncology Biosimilars Market Value Share, by Drug Class, 2017 and 2026
14.6 Europe Oncology Biosimilars Market Attractiveness, by Drug Class, 2017–2026
14.7 Europe Oncology Biosimilars Market Size (US$ Mn) Forecast, by Drug Class, 2015–2026
14.7.1 G-CSF
14.7.2 Monoclonal Antibody
14.7.3 Hematopoietic Agents
14.8 Europe Oncology Biosimilars Market Value Share, by Disease Indication, 2017 and 2026
14.9 Europe Oncology Biosimilars Market Attractiveness, by Disease Indication, 2017–2026
14.10 Europe Oncology Biosimilars Market Size (US$ Mn) Forecast, by Disease Indication, 2015–2026
14.10.1 Breast Cancer
14.10.2 Non-Small Cell lung Cancer
14.10.3 Blood Cancer
14.10.3.1 Leukemia
14.10.3.1.1 Myeloid Leukemia
14.10.3.1.2 Chronic Lymphocytic Leukemia
14.10.3.1.3 Others
14.10.3.2 Non-Hodgkin Lymphoma
14.10.4 Colorectal Cancer
14.10.5 Neutropenia
14.10.6 Others
14.11 Europe Oncology Biosimilars Market Value Share, by Distribution Channel, 2017 and 2026
14.12 Europe Oncology Biosimilars Market Attractiveness, by Distribution Channel, 2017–2026
14.13 Europe Oncology Biosimilars Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2026
14.13.1 Hospital Pharmacy
14.13.2 Online Pharmacy
14.13.3 Retail Pharmacy
14.14 Key Trends
Section 15 Asia Pacific Oncology Biosimilars Market Analysis and Forecast
15.1 Asia Pacific Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2015–2026
15.2 Asia Pacific Oncology Biosimilars Market Value Share, by Country, 2017 and 2026
15.3 Asia Pacific Oncology Biosimilars Market Attractiveness, by Country, 2017–2026
15.4 Asia Pacific Oncology Biosimilars Market Size (US$ Mn) Forecast, by Country, 2015–2026
15.4.1 China
15.4.2 India
15.4.3 Japan
15.4.4 Australia & New Zealand
15.4.5 Rest of Asia Pacific
15.5 Asia Pacific Oncology Biosimilars Market Value Share, by Drug Class, 2017 and 2026
15.6 Asia Pacific Oncology Biosimilars Market Attractiveness, by Drug Class, 2017–2026
15.7 Asia Pacific Oncology Biosimilars Market Size (US$ Mn) Forecast, by Drug Class, 2015–2026
15.7.1 G-CSF
15.7.2 Monoclonal Antibody
15.7.3 Hematopoietic Agents
15.8 Asia Pacific Oncology Biosimilars Market Value Share, by Disease Indication, 2017 and 2026
15.9 Asia Pacific Oncology Biosimilars Market Attractiveness, by Disease Indication, 2017–2026
15.10 Asia Pacific Oncology Biosimilars Market Size (US$ Mn) Forecast, by Disease Indication, 2015–2026
15.10.1 Breast Cancer
15.10.2 Non-Small Cell lung Cancer
15.10.3 Blood Cancer
15.10.3.1 Leukemia
15.10.3.1.1 Myeloid Leukemia
15.10.3.1.2 Chronic Lymphocytic Leukemia
15.10.3.1.3 Others
15.10.3.2 Non-Hodgkin Lymphoma
15.10.4 Colorectal Cancer
15.10.5 Neutropenia
15.10.6 Others
15.11 Asia Pacific Oncology Biosimilars Market Value Share, by Distribution Channel, 2017 and 2026
15.12 Asia Pacific Oncology Biosimilars Market Attractiveness, by Distribution Channel, 2017–2026
15.13 Asia Pacific Oncology Biosimilars Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2026
15.13.1 Hospital Pharmacy
15.13.2 Online Pharmacy
15.13.3 Retail Pharmacy
15.14 Key Trends
Section 16 Rest of the World Oncology Biosimilars Market Analysis and Forecast
16.1 Rest of the World Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2015–2026
16.2 Rest of the World Oncology Biosimilars Market Value Share, by Country, 2017 and 2026
16.3 Rest of the World Oncology Biosimilars Market Attractiveness, by Country, 2017–2026
16.4 Rest of the World Oncology Biosimilars Market Size (US$ Mn) Forecast, by Country, 2015–2026
16.4.1 Mexico
16.4.2 Brazil
16.4.3 Rest of the World
16.5 Rest of the World Oncology Biosimilars Market Value Share, by Drug Class, 2017 and 2026
16.6 Rest of the World Oncology Biosimilars Market Attractiveness, by Drug Class, 2017–2026
16.7 Rest of the World Oncology Biosimilars Market Size (US$ Mn) Forecast, by Drug Class, 2015–2026
16.7.1 G-CSF
16.7.2 Monoclonal Antibody
16.7.3 Hematopoietic Agents
16.8 Rest of the World Oncology Biosimilars Market Value Share, by Disease Indication, 2017 and 2026
16.9 Rest of the World Oncology Biosimilars Market Attractiveness, by Disease Indication, 2017–2026
16.10 Rest of the World Oncology Biosimilars Market Size (US$ Mn) Forecast, by Disease Indication, 2015–2026
16.10.1 Breast Cancer
16.10.2 Non-Small Cell lung Cancer
16.10.3 Blood Cancer
16.10.3.1 Leukemia
16.10.3.1.1 Myeloid Leukemia
16.10.3.1.2 Chronic Lymphocytic Leukemia
16.10.3.1.3 Others
16.10.3.2 Non-Hodgkin Lymphoma
16.10.4 Colorectal Cancer
16.10.5 Neutropenia
16.10.6 Others
16.11 Rest of the World Oncology Biosimilars Market Value Share, by Distribution Channel, 2017 and 2026
16.12 Rest of the World Oncology Biosimilars Market Attractiveness, by Distribution Channel, 2017–2026
16.13 Rest of the World Oncology Biosimilars Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2026
16.13.1 Hospital Pharmacy
16.13.2 Online Pharmacy
16.13.3 Retail Pharmacy
16.14 Key Trends
Section 17 Competition Landscape
17.1 Market Player – Competition Matrix (By Tier and Size of companies)
17.2 Market Share Analysis By Company (2016)
Section 18 Company Profiles
18.1 Sandoz International GmbH
18.1.1 Company Details
18.1.2 Business Overview
18.1.3 Financial Overview
18.1.4 Strategic Overview
18.1.5 SWOT Analysis
18.2 Pfizer, Inc.
18.2.1 Company Details
18.2.2 Business Overview
18.2.3 Financial Overview
18.2.4 Strategic Overview
18.2.5 SWOT Analysis
18.3 Celltrion Inc.
18.3.1 Company Details
18.3.2 Business Overview
18.3.3 Financial Overview
18.3.4 Strategic Overview
18.3.5 SWOT Analysis
18.4 Dr. Reddy’s Laboratories Ltd.
18.4.1 Company Details
18.4.2 Business Overview
18.4.3 Financial Overview
18.4.4 Strategic Overview
18.4.5 SWOT Analysis
18.5 Biocon
18.5.1 Company Details
18.5.2 Business Overview
18.5.3 Financial Overview
18.5.4 Strategic Overview
18.5.5 SWOT Analysis
18.6 Teva Pharmaceutical Industries Ltd.
18.6.1 Company Details
18.6.2 Business Overview
18.6.3 Financial Overview
18.6.4 Strategic Overview
18.6.5 SWOT Analysis
18.7 STADA Arzneimittel AG
18.7.1 Company Details
18.7.2 Business Overview
18.7.3 Financial Overview
18.7.4 Strategic Overview
18.7.5 SWOT Analysis
18.8 Apotex Inc. (Apobiologix)
18.8.1 Company Details
18.8.2 Business Overview
18.8.3 Financial Overview
18.8.4 Strategic Overview
18.8.5 SWOT Analysis
18.9 Intas Pharmaceuticals Ltd.
18.9.1 Company Details
18.9.2 Business Overview
18.9.3 Financial Overview
18.9.4 Strategic Overview
18.9.5 SWOT Analysis
18.10 BIOCAD
18.10.1 Company Details
18.10.2 Business Overview
18.10.3 Financial Overview
18.10.4 Strategic Overview
18.10.5 SWOT Analysis
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers